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Plasma insulin-like growth factors and bone formation in uremic
hyperparathyroidism. Bone formation in uremia is considered to be
regulated in part by parathyroid hormone (PTH). However, while low
levels of immunoreactive PTH are usually associated with low rates of
bone formation in uremia, elevated PTH levels do not always correlate
with increased bone formation. In an attempt to identify other factors
that may regulate bone formation in uremic patients, we measured
plasma immunoreactive insulin-like growth factors (IGF-I and IGF-ll)
in 15 patients who did not have aluminum-associated reductions in bone
formation. Plasma levels of IGF-1 but not PTH, were significantly
higher in patients with high rates of bone formation when compared to
patients with low or normal bone formation (P < 0.02). While the bone
formation rate at the tissue level correlated significantly with plasma
PTH (r = 0.53, P <0.05) and IGF-l (r = 0.67, P <0.01), only for plasma
IGF-I were there significant correlations with bone apposition (r = 0.57,
P < 0.05) and bone formation rate at the BMU level (r = 0.62, P <
0.02), parameters which reflect mineralization activity at the cellular
level. Among the static histologic parameters, osteoblastic osteoid
correlated only with plasma PTH (r = 0.76, P <0.001), while osteoclast
number correlated with both PTH (r = 0.56, P < 0.05) and IGF-I (r =
0.67, P < 0.01). There were no correlations between IGF-II levels and
bone histology. From these data we suggest that IGF-1 may promote
bone formation in uremic patients with hyperparathyroidism. The
mechanisms in which IGF-L and PTH enhance bone formation may be
different, however, since PTH but not IGF-I correlates with the index
for osteoblast number, and IGF-I correlates better with parameters of
bone mineralization. IGF-I may directly promote bone matrix mineral-
ization in vivo by stimulating either collagen synthesis or hydroxyapa-
tite formation, or both.
Elevated circulating levels of parathyroid hormone (PTH) are
predictive of high bone turnover in uremic patients [1—81. The
anabolic effect of PTH on uremic bone is attributed to enhanced
osteoblast activity [3, 8] which is consistent with in vitro studies
showing increased proliferation of human osteoblasts following
incubation with PTH [9]. Histologically, parameters of bone
formation have been shown to correlate directly with PTH
levels in several mixed population studies of uremic patients
[2—81. Taken together, these observations have suggested that
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PTH, when elevated, acts as a major stimulus for bone forma-
tion in renal osteodystrophy.
Recently, we demonstrated that plasma amino terminal PTH
was directly correlated with bone formation (r = 0.73; P <
0.001) in a large group of dialysis patients, with and without
aluminum-related bone disease [7], consistent with findings
from other studies in which amino-terminal PTH assays were
also utilized [3, 4]. However, it was also noted that the
correlation coefficient between PTH and bone formation was
substantially lower (r = 0.46) when patients with aluminum-
related bone disease were excluded from analysis [71. Because
aluminum is known to suppress both PTH secretion [10, 11] and
osteoblast activity [12, 13] in vitro, decreased bone formation in
aluminum-related bone disease is likely a consequence of the
direct effect of aluminum on bone [14] as well as the indirect
effect of lowered PTH levels [15, 16]. Thus, in uremic patients
with aluminum bone disease, aluminum and PTH appear to be
the major determinants of bone formation, while in those
without aluminum osteodystrophy PTH alone accounts for only
a portion of the stimulus for bone formation. This suggests to us
that, in addition to PTH, other circulating factors may be
involved in the regulation of bone formation in uremic hyper-
parathyroidism.
Insulin-like growth factors (IGFs) are a group of peptides
which have growth promoting effects in a variety of cells [17].
In bone organ cultures, Canalis has shown that IGF-I increases
DNA and collagen synthesis [18] and Howard and Spencer have
shown similar responses to purified IGF-I and IGF-II in chick
osteoblast monolayers [19]. More recently, Kurose et al have
shown that IGF-I stimulates alkaline phosphatase activity in
clonal osteoblasts [20], suggesting a possible role for IGFs in
bone mineralization. Because IGFs appear to have an anabolic
effect on bone in vitro and since increased IGF levels have been
reported in patients undergoing dialysis [211, we reasoned that
elevated IGF levels may result in increased bone formation in
uremia. Thus, the purpose of this study was to determine
whether elevated plasma IGFs are associated with enhanced
bone formation in uremic patients without aluminum toxicity
and to compare the relationships that the IGFs and PTH may
have with parameters of bone formation in patients with sec-
ondary hyperparathyroidism.
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Methods
Patients
Previously obtained bone biopsies (double-tetracycline la-
beled) in 15 patients with chronic renal failure (12 men and 3
women) were selected from a group of 26 patients on the basis
of: 1) biopsies having less than 10% stainable bone surface
aluminum and 2) the availability of frozen plasma which was
obtained within one week of the biopsy. Patients with excess
aluminum on bone were excluded because of the suppressive
effects of aluminum on bone formation [8, 141 and on PTH
secretion [10, 15]. All patients were undergoing thrice weekly
hemodialysis either at home or in regional centers. Their mean
(±sE) age was 42 3 years and their mean (±sE) duration of
dialysis was 65 18 months. None had evidence of liver or
thyroid disease, and none had received immunosuppressive
therapy prior to the bone biopsy. Six patients were receiving
oral calcitriol (mean dose, 0.3 /.Lg/day) and seven patients were
receiving calcium carbonate at the time of study. Two patients
received both calcitriol and calcium carbonate, and all of the
patients were receiving aluminum-containing phosphate bind-
ers. There were two patients with diabetes mellitus and two
patients who had undergone parathyroidectomy for secondary
hyperparathyroidism two and four years before their biopsies.
The amino-terminal PTH levels in these patients were 3.5- and
20-fold above the upper normal limit, respectively, at the time
of study. All were active and otherwise healthy with no history
of recent weight loss.
Biocheniistries
Serum calcium, phosphorus, alkaline phosphatase and albu-
min were determined with an autoanalyzer. Blood for PTH and
IGF measurements was obtained before hemodialysis, centri-
fuged in heparinized tubes and the plasma immediately frozen
at —20°C. Immunoreactive PTH was measured in duplicate
utilizing an amino-terminal antiserum (CK-67) raised against
synthetic human PTH (1-34) [22]. This cross reacts with intact
PTH (1-84] but not with mid-region/carboxy-terminal PTH
fragments. The normal mean (±sD) is 18 3 pg/mI (N = 61)
with a range of 8 to 24 pg/ml. Plasma IGFs were assayed by
radioimmunoassay after extraction with acid-ethanol. The
method for acid-ethanol extraction by Daughaday, Mariz and
Blethen [23] was utilized in which 0.2 ml of plasma sample was
treated with 0.8 ml of acidifIed ethanol for 30 minutes at room
temperature. The precipitate was removed by centrifugation
and the supernatant neutralized with tris base. The neutralized
fraction was then diluted and assayed for IGF-I and IGF-II. The
RIA for IGF-I was a procedure described by Copeland, Under-
wood and Van Wyk [24] in which serum based secondary
standard was used routinely. The secondary standard was
extracted as above and calibrated against a highly purified
IGF-I preparation. Samples were pre-incubated for one hour at
22°C before incubating with '251-labeled IGF-I (from Nichols
Institute Diagnostic) for 18 hours at 4°C. Antibody-'251-IGF-I
complexes were then precipitated by goat anti-rabbit gamma
globulin precipitating antibody at 4°C and the bound radioac-
tivity in the pellet was counted. The assay has a 2% cross
reactivity with IGF-II and <0.01% cross reactivity with prom-
sulin and pituitary growth hormone. The intra-assay variation is
4.8% and interassay variation is 9.8%. The normal mean (± SD)
is 141 21 ng/ml (N 95) with a range ofSl to 285 ng/ml. The
RIA for IGF-II, which uses a monoclonal antibody (from
Amano mt. Enzyme Corp., Troy, Virginia, USA), is performed
at equilibrium by simultaneous addition of sample and antibody
tracer at 4°C for 20 hours. (The '251-labeled IGF-II was from
Drs. Van Wyk and Underwood.) The bound/free separation is
achieved using goat anti-mouse gamma globulin. The antibody
has 9.6% cross reactivity with IGF-I and <0.01% cross reac-
tivity with proinsulin, insulin, human epidermal growth factor
and pituitary growth hormone. The assay is sensitive to 0.2
ng/ml (at 90% B/Bo) using a highly purified standard. The
intra-assay variation is 5.3% and interassay variation is 8.6%.
The normal mean (± SD) is 606 124 (N = 20) with a range of
358 to 854 ng/ml.
Bone histomorphometry
Histomorphometric analysis of Goldner's stained sections
was done as previously described [7]. Static histologic measure-
ments of trabecular bone included osteoid area (as percent of
total bone area), osteoid width (tm), osteoblastic osteoid
(cuboidal or "plump" osteoblasts) as percent of total bone
surface, resorptive surface (as percent of total bone surface),
and osteoclast number (expressed as number per mm of bone
surface). Normal values for the static parameters used for these
comparisons were obtained in our laboratory from 14 male and
6 female subjects (age range, 21 to 59 years). The dynamic
measurements were made on unstained trabecular sections and
included bone apposition rate (BAR; pm/day) and the length of
double-labeled surfaces (Ldl; as percent of total bone surface
and as percent of osteoid surface). From these values, the bone
formation rate (BFR) at the tissue level was derived by multi-
plying the bone apposition rate by the double-labeled surfaces,
according to the method of Vedi et al [25]. The BFR at the BMU
(basic multicellular unit) level was calculated by dividing the
BFR at the tissue level by the length of the osteoid surface
(expressed as a decimal fraction of the total trabecular surface).
Normal values for the dynamic parameters were obtained from
the same subjects used in the evaluation of the static parame-
ters.
Statistics
All results are expressed as the mean unless stated
otherwise. The Mann-Whitney rank sum test was used for
group comparisons and correlation coefficients were deter-
mined using the Spearman rank test for nonparametric regres-
sions with P < 0,05 taken as the minimum level of significance.
Multiple linear regression analysis was performed as indicated.
All computations were performed using the BMDP statistical
package (University of California Press, Berkeley, California,
USA).
Results
Serum calcium and phosphorus levels were normal or above
normal in all patients (Table 1). Serum albumin ranged from 2.9
to 4.5 g/dl with two patients having values below the lower
normal limit (2.9 g/dl and 3.4 g/dl, respectively). Plasma PTH
levels were markedly elevated in the majority of patients; only
two values were in the normal range. Similarly, plasma IGF-I
and IGF-II were above the upper normal limit in 47% and 60%
of the patients, respectively. There were no significant correla-
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Table 1. Biochemical parameters in 15 dialysis patients with
hyperparathyroidism
Biochemistries Patients Normal
Calcium mg/dl 10.4 0.2 8.5—10.5
Phosphorus mg/dl 5.9 0.3 2.5—4.5
Albumin gIdi 3.9 0.1 3.5—5.5
Alkaline phosphatase U/liter 188 38 15—75
PTH pg/mi 134 33 18 1'
IGF-I ng/ml 343 47 141 2"
IGF-I1 ng/ml 914 58 606 28C
Values are the mean SE.
aN = 61b N = 95
N = 20
Table 2. Bone histomorphometry in IS dialysis patients and 20
normal subjects
Histologic parameters Patients Normala
Osteoid area % total bone area 6 1 4 I
Osteoblastic osteoid % of total surface 9 2b 3.4 0.6
Osteoclasts no.1mm surface 3.8 0.9c 0.4 0.1
Resorption % total surface 17 2 6 1
Fibrosis % tissue area 1.7 0.5 0
BAR /1m/day 0.96 008d 0.61 0.02
BFR, tissue level um3/jsm2/day
BFR, BMU level p.m3/p.rn2/day
0.235 0125b
0.495 0.082
0.085 0.01
0.30 0.11
Ldl % total surface 22 4 14 I
Ldi % osteoid surface 47 6 48 4
Values are the mean SE.
a Normal values for osteoblastic osteoid and osteoclast number
included 13 and 7 subjects, respectivelyb P = 0.02
C P < 0.01
d P < 0.001
tions of plasma PTH with IGF-I or with IGF-II and serum
albumin did not correlate with either of the plasma IGFs.
To determine whether unsaturated IGF carrier protein was
incompletely removed from plasma by the acid-ethanol extrac-
tion method, plasma was obtained from five additional dialysis
patients and five normal subjects and applied to columns of C,8
silica (SepPak; Waters Associates, Milford, Massachusetts,
USA) as described by Daughaday, Kapadia and Mariz [26].
Briefly, the plasma samples were acidified with 0.5 N HCI and
the carrier proteins removed with washes of 4% acetic acid.
IGF-I was then eluted with 50% acetonitrile and quantitated by
RIA. In the uremic patients the mean (± SD) IGF-I level after
acid-ethanol extraction was 187 52 nglml and after SepPak
extraction, 219 49 ng/ml. In the normal subjects the mean
IGF-I level was 125 14 ng!ml after acid-ethanol extraction,
and 140 13 ng/ml after SepPak extraction.
All except three of the bone biopsies exhibited histologic
values that were either above normal or within the normal range
for the parameters evaluated, indicating high-turnover hyper-
parathyroidism (Table 2). The exceptions were two biopsies
which had low values for osteoblastic osteoid (0.5 and 1.2%)
and one biopsy which had a low bone formation rate at the
tissue level (0.014 m3/m2/day). This latter biopsy, which was
obtained from one of the patients with diabetes, did not show
osteomalacia (normal osteoid width and osteoid area). Overall
there were seven biopsies with elevated rates of BFR (tissue
BFR, tissue level, m3/m2Iday
Fig. 1. Comparisons of plasma IGF-I and PTH in dialysis patients with
rates of bone formation below and above 0.20 ,um3Im2/day (upper
normal limit). The shaded areas represent normal ranges.
level). Six of these had a BFR that was greater than five
standard deviations above the normal mean (the highest BFR
was 11 standard deviations above the normal mean). Marrow
fibrosis was moderate in three patients (fibrosis area 0.5 to 2.0%
of total tissue area) and severe in six patients (fibrosis area
>2.0% of total tissue area).
Displayed in Figure 1 are the comparisons of plasma IGF-I
and PTH in relation to the BFR at the tissue level. Among the
patients with rates of bone formation greater than the upper
normal limit (0.2 p.m3/im2/day), all but one had IGF-I levels
that exceeded 300 ng/ml whereas none in the group with a
normal or low BFR (<0.2 m3/m2/day) had IGF-I levels above
300 ng/ml. The mean IGF-I levels were significantly different
between the two groups (242 19 vs. 459 80 nglml, P < 0.02).
In contrast, the groups with high rates of bone formation did not
have PTH levels that were significantly higher than the low
BFR group (183 56 vs. 67 28, P = 0.17).
In Table 3 are the correlation coefficients for the comparisons
of the bone histological parameters and plasma PTH, IGF-I,
and IGF-II. Plasma PTH correlated with BFR at the tissue level
and the double-labeled surfaces but not with BFR at the BMU
level (r = 0.30) nor with BAR (r = 0.23). In contrast, plasma
IGF-I correlated with all the dynamic parameters including
BFR at the BMU level (r = 0.62, P < 0.02) and BAR (r = 0.57,
P < 0.05). Among the static histologic parameters, osteoblastic
osteoid was highly correlated with PTH (r = 0.76, P <0.001),
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Table 3. Correlation coefficients between bone histological
parameters and plasma PTH, IGF-I and IGF-II
Parameters PTH IGF-l IGF-lL
Dynamic parameters
BFR, tissue level pm3Ip.m2/day 067b 0.33
BFR, BMU level .un3/um2/day
BAR pin/day
0.30
0.23
0.62'
057"
0.35
0.32
LDI
% total surface 052" 068b 0.34
% osteoid surface 053d 0.62" 0.39
Static parameters
Osteoblastic osteoid
% total surface 0.76a 0.39 0.13
Osteoid area
% total bone area 0.35 0.11 —0.05
Osteoclasts no.1mm surface
Resorption % total surface
0.56"
0.67"
0.67"
0.43
0.29
0.48
a p < 0.001
b P < 0.01
"P < 0.02d p < 0,05
Table 4. Dynamic bone histologic parameters in dialysis patients
with normal and elevated plasma IGF-I
Plasma IGFIa
Normal Elevated
Histologic parameters N = 7 N = 8
BFR tissue level 0.128 0.044 0.357 0.062"
p.m3lpin2lday
BFR, BMU level 0.269 0.077 0.753 0.067C
pin3/pin2/day
BAR pin/day 0.75 0.08 1.20 0.08"
Ldl % total surface 15 4 31 5d
Ldl % osteoid surface 33 6 64 5"
Values are mean SE.
a normal range, SI to 285 ng/ml.b P = 0.02 vs. group with normal IGF-I levels
P < 0.01 vs. group with normal IGF-I levels
"P = 0.03 vs. group with normal IGF-I levels
patients receiving calcium carbonate (with or without calcitriol)
and the group not receiving calcium carbonate.
Discussion
but not with plasma IGF-I (r = 0.39). Both plasma PTH and
IGF-I correlated with osteoclast number and neither correlated
with mineralized bone area. There were no significant correla-
tions between plasma IGF-II and bone histology. Shown in
Figures 2 and 3 are the relationships between plasma PTH and
IGF-I compared to BFR at the tissue level and to osteoblastic
osteoid. Stepwise linear regression analysis using PTH and
IGF-I as independent variables revealed no improvement in the
prediction of any of the dynamic or static histologic parameters.
As shown in Table 4, all of the dynamic bone parameters
listed are significantly higher in the group of patients whose
plasma IGF-I levels were elevated above the upper normal limit
(>285 pg/mI) compared to those with parameters in the normal
range. In addition, the group with elevated IGF-I levels, when
compared to normal subjects, also had higher rates of bone
formation (P 0.02) as well as higher values for BAR (P <
0.01), BFR at the BMU level (P < 0.01), Ldl as % of total
surface (P = 0.03) and Ldl as % of osteoid surface (P < 0.01).
Evidence of coupling between bone formation and bone
resorption is provided by the positive correlation between
osteoblastic osteoid and osteoclast number (r = 0.83, P <
0.0001) and the correlation between BFR (tissue level) and
osteoclast number (r = 0.78, P < 0.001).
The bone histologic parameters and serum biochemistries
were not different between the group of patients that was
receiving oral calcitriol (N = 6) and the group not taking
calcitriol (N = 9). In the calcitriol group (mean dose of
calcitriol, 0.3 j.tglday), the mean (±sD) bone formation rate
(tissue level) was 0.14 0.11 rm3/sm2/day and the osteoblastic
osteoid was 6.8 4.3%. These values are not significantly
different from the group not receiving calcitriol: bone formation
rate, 0.30 0.20 prn3/sm2/day and osteoblastic osteoid, 10.7
8.2%. Moreover, in the calcitriol group, the mean (±sD) serum
levels of calcium (10.7 1.0 mg/dl), PTH (121 96 pg/mI) and
IGF-I (313 195 ng/ml) are not different from the group not
receiving calcitriol: calcium, 10.2 0.7; PTH, 149 147 pg/mI;
and IGF-I, 350 188 nglml. Finally, there are no differences in
bone histology or serum biochemistries between the group of
The finding that plasma IGF-I correlates directly with BFR
suggests that this circulating growth factor may be important in
promoting bone mineralization in uremia. While correlations of
this type do not prove a cause and effect relationship, the
finding that patients with elevated plasma IGF-I levels had
significantly higher values for all the parameters of bone forma-
tion, when compared to those with lower IGF-I levels (Table 4),
strengthens the argument for IGF-I having a role in the miner-
alization process. The exact mechanism in which IGF-I may be
anabolic for bone cannot be determined from this study. How-
ever, the data suggest that IGF-I may promote bone formation
by an effect that is independent of enhanced osteoblast prolif-
eration since IGF-I levels did not correlate with osteoblastic
osteoid, an indicator of osteoblast number. Instead, because of
the correlations of plasma IGF-I with BAR, Ldl and BFR at the
BMU level, IGF-I may be more important in promoting the
mineralization of individual bone forming units by either en-
hancing collagen synthesis or by stimulating the osteoblastic
formation of alkaline phosphatase which may be important in
the deposition of hydroxyapatite crystals. IGF-I in physiologic
concentrations stimulates collagen synthesis in organ bone
cultures [18], an effect that is not entirely due to enhanced bone
cell proliferation [27]. Moreover, IGF-I increases alkaline phos-
phatase activity in murine clonal osteoblasts [20]. These data,
therefore, strongly suggest that elevated circulating IGF-I may
stimulate osteoblast differentiation and thereby directly pro-
mote bone mineralization in vivo. The results do not, however,
exclude the possibility that the osteoblastic production of IGF-I
[281 is also involved in regulating bone formation locally.
Our results are consistent with other reports showing a
positive correlation between PTH and various parameters of
bone formation in uremia [2—7]. We did not, however, find a
significant correlation between PTH and the bone apposition
rate as reported elsewhere [7]. The major difference between
the current study and earlier reports is our exclusion of patients
with aluminum bone disease which was done to eliminate
aluminum as a cause of impaired mineralization. Thus, in our
study the lack of significant correlations of PTH with BAR and
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A r 0.67
P < 0.01
I I I I I
150 300 450 600 750
Plasma IGF-l
ng/mi
B r = 0.53
P< 0.05
B r = 0.76
P < 0.01
I I I I I
100 200 300 400 500
Plasma PTH
pg/mi
Fig. 2. Relationship of BFR, tissue level to
plasma IGF-I (A) and to plasma PTH (B).
with BFR at the BMU level and the finding that PTH was highly
correlated with osteoblastic osteoid suggest that PTH enhances
bone formation in uremia primarily by increasing the number of
active osteoblasts. Our finding of a positive correlation between
PTH and the double-tetracycline labeled surface (Ldl) is attrib-
uted to this relationship between PTH and osteoblastic osteoid.
Since studies in cultured human bone cell monolayers 191 as
well as in rat organ bone cultures [29, 30] have shown that PTH
stimulates cell proliferation [9, 30] but decreases collagen
synthesis [291, these data would support our suggestion that
PTH and IGF-I may have different effects on osteoblast func-
tion in vivo.
In addition to the positive correlations between IGF-I and
parameters of bone formation, we found that plasma IGF-I also
correlated with osteoclast number (r = 0.67, P < 0.01). While it
is possible that IGF-I may stimulate osteoclast activity directly,
IGF-I receptors on osteoclasts must first be identified before
this can be accepted. A more likely explanation for the corre-
lation is that bone resorption and bone formation have remained
coupled in our patients since osteoclast number was highly
correlated with osteoblastic osteoid (r = 0.83) and BFR (r =
0.78). Thus, any stimulus to bone formation, through an effect
on the osteoblast, will also increase osteoclast activity and bone
resorption. Presently, this is also the explanation for the posi-
tive correlation between PTH and osteoclast number, since
PTH receptors are lacking in mature osteoclasts [31].
Plasma immunoreactive IGF levels were above the normal
range in the majority of our uremic patients. While other studies
have reported variable levels of the IGFs in uremic serum [21,
32, 33], none have shown an association between circulating
levels and a particular biologic response in this patient popula-
tion. Because the IGFs circulate bound to large carrier proteins,
acid-ethanol pre-treatment of serum samples has been advo-
cated to ensure reliable quantitation of total IGF-I and IGF-II
[23]. Recently, it has been proposed that uremic serum contains
excess amounts of unsaturated carrier protein which are not
completely removed by acid-ethanol extraction, and that under-
estimation of immunoreactive IGF-I levels can occur as a result
of poor separation of antibody and carrier protein by polyeth-
ylene glycol [33]. In our IGF radioimmunoassays, a second
antibody is used to separate bound from free radioligand, which
is more specific than polyethylene glycol in the separation step
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Fig. 3. Relationship of osteoblastic osteoid to
plasma IGF-I (A) and to plasma PTH (B).
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[261. Consequently, unsaturated carrier protein bound to '"i-
IGF-I is not precipitated and counted. This explains why the
acid-ethanol treated samples from our uremic patients were not
lower than normal, in contrast to the results of Powell et a! in
which polyethylene glycol was used to precipitate the antibody
[331. While acid-ethanol extraction may not completely remove
IGF-carrier proteins from uremic plasma, IGF-I levels are
underestimated in our RIA by an average of only 17% when
compared to IGF-I levels in plasma previously extracted on
columns of C13 silica to remove carrier protein. Thus, the IGF
levels in our patients are an accurate reflection of total IGF-I
and are significantly elevated above normal.
The cause of the increased immunoreactive IGF levels in our
patients is not apparent. It is possible that IGF production in the
liver was stimulated by growth hormone since elevated levels of
growth hormone have been observed in uremia [34, 35]. It is
also possible that heparinization during dialysis may have
contributed to altered IGF levels since heparin is known to
prevent binding of IGF-I to its carrier protein [36]. However,
we did not find higher IGF-I levels in heparinized uremic
plasma when compared to uremic serum from the same patients
(data not shown). It is also unlikely that individual differences in
the amount of heparin administered during dialysis affected the
IGF-I determinations since our patients received similar con-
centrations of heparin throughout their dialytic treatments and
because the plasma measurements were made at least 40 hours
after the last heparin infusion.
We do not believe the plasma levels of the IGFs were affected
by differences in nutrition. All of our patients were well
nourished clinically (only 2 patients had serum albumin levels
that were slightly below the lower normal limit) and none had
recent weight loss. Furthermore, the serum albumin did not
correlate with plasma IGF levels. However, since protein
restriction can result in decreased circulating IGF-I [37], this
potential situation in a dialysis patient could make IGF-I levels
poor predictors of bone formation.
Despite finding a significant relationship between plasma
IGF-I and bone histology in this study, we cannot rule out the
possibility that circulating IGF inhibitors may also have a role
in the bone response to IGF-I. Phillips Ct al have recently
shown that whole uremic serum has decreased IGF activity, as
determined by bioassay, primarily as a result of elevated levels
of a low molecular weight (<1,000 daltons) inhibitor [38].
Theoretically, this inhibitor could attenuate any anabolic effect
that IGF-I may have on bone. This may partially explain why in
our study the correlation coefficient between IGF-I and BFR
was only 0.67 (R2 value, 0.45). It remains to be shown,
however, whether such inhibitors of IGF action correlate with
bone function in uremia, either by inhibiting osteoblast prolif-
eration or by preventing normal bone mineralization.
In summary, we have found that immunoreactive IGF-I
levels are directly correlated with rates of bone formation and
bone apposition in uremic patients with hyperparathyroidism,
suggesting a possible role for IGF-I in promoting bone miner-
alization. Because both plasma PTH and IGF-I correlate with
the bone formation rate at the tissue level but only PTH
correlates with the index for osteoblast number, we conclude
that PTH and IGF-I may enhance bone formation by different
mechanisms. Future studies should investigate the relative
contribution of IGF-I in promoting collagen synthesis and
hydroxyapatite formation in human bone.
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